These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
874 related articles for article (PubMed ID: 29655611)
21. Assessment of PSMA targeting ligands bearing novel chelates with application to theranostics: Stability and complexation kinetics of Kelly JM; Amor-Coarasa A; Nikolopoulou A; Kim D; Williams C; Vallabhajosula S; Babich JW Nucl Med Biol; 2017 Dec; 55():38-46. PubMed ID: 29055836 [TBL] [Abstract][Full Text] [Related]
22. Design of Internalizing PSMA-specific Glu-ureido-based Radiotherapeuticals. Wüstemann T; Bauder-Wüst U; Schäfer M; Eder M; Benesova M; Leotta K; Kratochwil C; Haberkorn U; Kopka K; Mier W Theranostics; 2016; 6(8):1085-95. PubMed ID: 27279903 [TBL] [Abstract][Full Text] [Related]
23. 2-(3-{1-Carboxy-5-[(6-[18F]fluoro-pyridine-3-carbonyl)-amino]-pentyl}-ureido)-pentanedioic acid, [18F]DCFPyL, a PSMA-based PET imaging agent for prostate cancer. Chen Y; Pullambhatla M; Foss CA; Byun Y; Nimmagadda S; Senthamizhchelvan S; Sgouros G; Mease RC; Pomper MG Clin Cancer Res; 2011 Dec; 17(24):7645-53. PubMed ID: 22042970 [TBL] [Abstract][Full Text] [Related]
25. What a difference a methylene makes: replacing Glu with Asp or Aad in the Lys-urea-Glu pharmacophore of PSMA-targeting radioligands to reduce kidney and salivary gland uptake. Kuo HT; Lin KS; Zhang Z; Zhang C; Merkens H; Tan R; Roxin A; Uribe CF; Bénard F Theranostics; 2022; 12(14):6179-6188. PubMed ID: 36168623 [TBL] [Abstract][Full Text] [Related]
26. Preclinical Evaluation of Cardinale J; Schäfer M; Benešová M; Bauder-Wüst U; Leotta K; Eder M; Neels OC; Haberkorn U; Giesel FL; Kopka K J Nucl Med; 2017 Mar; 58(3):425-431. PubMed ID: 27789722 [TBL] [Abstract][Full Text] [Related]
27. A new (68)Ga-labeled BBN peptide with a hydrophilic linker for GRPR-targeted tumor imaging. Pan D; Xu YP; Yang RH; Wang L; Chen F; Luo S; Yang M; Yan Y Amino Acids; 2014 Jun; 46(6):1481-9. PubMed ID: 24633452 [TBL] [Abstract][Full Text] [Related]
28. Duan X; Cao Z; Zhu H; Liu C; Zhang X; Zhang J; Ren Y; Liu F; Cai X; Guo X; Xi Z; Pomper MG; Yang Z; Fan Y; Yang X Eur J Nucl Med Mol Imaging; 2022 Feb; 49(3):1030-1040. PubMed ID: 34453203 [TBL] [Abstract][Full Text] [Related]
29. Improve the Biodistribution with Bulky and Lipophilic Modification Strategies on Lys-Urea-Glu-Based PSMA-Targeting Radiotracers. Cai P; Tang S; Xia L; Wang Y; Liu Y; Feng Y; Liu N; Chen Y; Zhou Z Mol Pharm; 2023 Feb; 20(2):1435-1446. PubMed ID: 36696174 [TBL] [Abstract][Full Text] [Related]
30. Clinical Translation and First In-Human Use of [ Eppard E; de la Fuente A; Benešová M; Khawar A; Bundschuh RA; Gärtner FC; Kreppel B; Kopka K; Essler M; Rösch F Theranostics; 2017; 7(18):4359-4369. PubMed ID: 29158832 [TBL] [Abstract][Full Text] [Related]
31. Development of Potemkin R; Strauch B; Kuwert T; Prante O; Maschauer S Mol Pharm; 2020 Mar; 17(3):933-943. PubMed ID: 32011889 [TBL] [Abstract][Full Text] [Related]
32. Development of Novel PSMA Ligands for Imaging and Therapy with Copper Isotopes. Carlos Dos Santos J; Beijer B; Bauder-Wüst U; Schäfer M; Leotta K; Eder M; Benešová M; Kleist C; Giesel F; Kratochwil C; Kopka K; Haberkorn U; Mier W J Nucl Med; 2020 Jan; 61(1):70-79. PubMed ID: 31541034 [TBL] [Abstract][Full Text] [Related]
33. 68Ga- and 177Lu-Labeled PSMA I&T: Optimization of a PSMA-Targeted Theranostic Concept and First Proof-of-Concept Human Studies. Weineisen M; Schottelius M; Simecek J; Baum RP; Yildiz A; Beykan S; Kulkarni HR; Lassmann M; Klette I; Eiber M; Schwaiger M; Wester HJ J Nucl Med; 2015 Aug; 56(8):1169-76. PubMed ID: 26089548 [TBL] [Abstract][Full Text] [Related]
34. Albumin-Binding PSMA Ligands: Optimization of the Tissue Distribution Profile. Benešová M; Umbricht CA; Schibli R; Müller C Mol Pharm; 2018 Mar; 15(3):934-946. PubMed ID: 29400475 [TBL] [Abstract][Full Text] [Related]
35. Comparative Evaluation of Using NOTA and DOTA Derivatives as Bifunctional Chelating Agents in the Preparation of Guleria M; Das T; Amirdhanayagam J; Sarma HD; Dash A Cancer Biother Radiopharm; 2018 Feb; 33(1):8-16. PubMed ID: 29373046 [TBL] [Abstract][Full Text] [Related]
36. Preparation of Wang Y; Shao G; Wu J; Cui C; Zang S; Qiu F; Jia R; Wang Z; Wang F Contrast Media Mol Imaging; 2018; 2018():8046541. PubMed ID: 29853810 [TBL] [Abstract][Full Text] [Related]
37. Synthesis, Labeling and Preclinical Evaluation of a Squaric Acid Containing PSMA Inhibitor Labeled with Greifenstein L; Engelbogen N; Lahnif H; Sinnes JP; Bergmann R; Bachmann M; Rösch F ChemMedChem; 2020 Apr; 15(8):695-704. PubMed ID: 32057189 [TBL] [Abstract][Full Text] [Related]
38. Cold Kit for Prostate-Specific Membrane Antigen (PSMA) PET Imaging: Phase 1 Study of Hofman MS; Eu P; Jackson P; Hong E; Binns D; Iravani A; Murphy D; Mitchell C; Siva S; Hicks RJ; Young JD; Blower PJ; Mullen GE J Nucl Med; 2018 Apr; 59(4):625-631. PubMed ID: 28986512 [No Abstract] [Full Text] [Related]
39. Tumor Uptake of Triazine Dendrimers Decorated with Four, Sixteen, and Sixty-Four PSMA-Targeted Ligands: Passive versus Active Tumor Targeting. Lim J; Guan B; Nham K; Hao G; Sun X; Simanek EE Biomolecules; 2019 Aug; 9(9):. PubMed ID: 31466360 [TBL] [Abstract][Full Text] [Related]
40. Preclinical Development of Novel PSMA-Targeting Radioligands: Modulation of Albumin-Binding Properties To Improve Prostate Cancer Therapy. Umbricht CA; Benešová M; Schibli R; Müller C Mol Pharm; 2018 Jun; 15(6):2297-2306. PubMed ID: 29684274 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]